Generalized versus localized vitiligo after ixekizumab: May previous treatment affect the clinical presentation?

Dermatol Ther. 2022 Dec;35(12):e15874. doi: 10.1111/dth.15874. Epub 2022 Oct 10.

Authors

Fabrizio Martora¹, Teresa Battista¹, Luigi Fornaro¹, Gabriella Fabbrocini¹, Matteo Megna¹, Vincenzo Picone¹, Claudio Marasca¹

Affiliation

¹ Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

PMID: 36181259
DOI: 10.1111/dth.15874

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Humans
Vitiligo* / chemically induced
Vitiligo* / diagnosis
Vitiligo* / drug therapy

Substances

ixekizumab
Antibodies, Monoclonal, Humanized